Page 140 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology KRAS TP53 cholangiocarcinoma

36. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of resection for hilar cholangiocarcinoma. Cancers (Basel).
tumor TROP2 expression with prognosis varies among lung 2022;14(18):4370.
cancer subtypes. Oncotarget. 2017;8(17):28725-28735.
doi: 10.3390/cancers14184370
doi: 10.18632/oncotarget.15647
47. Robertson S, Hyder O, Dodson R, et al. The frequency of KRAS
37. Putra J, De Abreu FB, Peterson JD, et al. Molecular profiling of and BRAF mutations in intrahepatic cholangiocarcinomas
intrahepatic and extrahepatic cholangiocarcinoma using next and their correlation with clinical outcome. Hum Pathol.
generation sequencing. Exp Mol Pathol. 2015;99(2):240-244. 2013;44(12):2768-2773.
doi: 10.1016/j.yexmp.2015.07.005 doi: 10.1016/j.humpath.2013.07.026
38. Tsilimigras DI, Stecko H, Moris D, Pawlik TM. Genomic 48. Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: Utility
profiling of biliary tract cancers: Comprehensive assessment of next-generation sequencing for clinical management.
of anatomic and geographic heterogeneity, co-alterations Cancer. 2016;122(24):3838-3847.
and outcomes. J Surg Oncol. 2025.
doi: 10.1002/cncr.30254
doi: 10.1002/jso.28081
49. Jin B, Wang Y, Zhang B, et al. Immune checkpoint inhibitor-
39. Huang X, Du G, Yang Y, et al. Advancing bladder cancer related molecular markers predict prognosis in extrahepatic
management: Development of a prognostic model and cholangiocarcinoma. Cancer Med. 2023;12(20):20470-20481.
personalized therapy. Front Immunol. 2024;15:1430792.
doi: 10.1002/cam4.6441
doi: 10.3389/fimmu.2024.1430792
50. Ikeno Y, Seo S, Iwaisako K, et al. Preoperative metabolic
40. Wang L, Li J, Mei N, et al. Identifying subtypes and developing tumor volume of intrahepatic cholangiocarcinoma
prognostic models based on N6-methyladenosine and measured by F-FDG-PET is associated with the KRAS
18
immune microenvironment related genes in breast cancer. mutation status and prognosis. J Transl Med. 2018;16(1):95.
Sci Rep. 2024;14(1):16586.
doi: 10.1186/s12967-018-1475-x
doi: 10.1038/s41598-024-67477-w
51. Conci S, Ruzzenente A, Simbolo M, et al. Multigene
41. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma:
Epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19-31. mutational profiling of biliary tract cancer is related to the
pattern of recurrence in surgically resected patients. Updates
doi: 10.1111/liv.14095 Surg. 2020;72(1):119-128.
42. Khuntikeo N, Andrews RH, Petney TN, Khan SA. doi: 10.1007/s13304-020-00718-5
Introduction. Recent Results Cancer Res. 2023;219:1-5.
52. Chao J, Wang S, Wang H, et al. Real-world cohort study of
doi: 10.1007/978-3-031-35166-2_1 PD-1 blockade plus lenvatinib for advanced intrahepatic
43. Tan S, Machrumnizar M. Fish and food-fatale: Food-borne cholangiocarcinoma: Effectiveness, safety, and biomarker
trematode opisthorchis viverrini and cholangiocarcinoma. analysis. Cancer Immunol Immunother. 2023;72(11):3717-3726.
Helminthologia. 2023;60(4):287-299. doi: 10.1007/s00262-023-03523-2
doi: 10.2478/helm-2023-0036 53. Chen TC, Jan YY, Yeh TS. K-ras mutation is strongly
44. Boerner T, Drill E, Pak LM, et al. Genetic determinants of associated with perineural invasion and represents
outcome in intrahepatic cholangiocarcinoma. Hepatology. an independent prognostic factor of intrahepatic
2021;74(3):1429-1444. cholangiocarcinoma after hepatectomy. Ann Surg Oncol.
2012;19(Suppl 3):S675-S681.
doi: 10.1002/hep.31829
doi: 10.1245/s10434-012-2224-7
45. Guo L, Zhou F, Liu H, et al. Genomic mutation characteristics
and prognosis of biliary tract cancer. Am J Transl Res. 54. Churi CR, Shroff R, Wang Y, et al. Mutation profiling
2022;14(7):4990-5002. in cholangiocarcinoma: Prognostic and therapeutic
implications. PLoS One. 2014;9(12):e115383.
46. Ardito F, Razionale F, Campisi A, et al. The impact of KRAS
mutational status on long-term survival following liver doi: 10.1371/journal.pone.0115383

Volume 9 Issue 3 (2025) 132 doi: 10.36922/EJMO025120063